Heart failure modulates electropharmacological characteristics of sinoatrial nodes

Shih Lin Chang, Hui Lun Chuang, Yao Chang Chen, Yu Hsun Kao, Yung Kuo Lin, Yung Hsin Yeh, Shih Ann Chen, Yi Jen Chen

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The impact of heart failure (HF) on sinoatrial node (SAN) channel regulation and electropharmacological responses has remained elusive. The present study aimed to investigate the effects of HF on the electrical activity of SANs with and without pharmacological interventions. Action potentials (APs) were recorded in isolated SANs from normal rabbits (control) and those with HF (rapid ventricular pacing for 4 weeks) prior to and after administration of a funny current blocker (ivabradine; 0.1, 0.3, 3 or 10 μM), a calmodulin kinase II inhibitor (KN 93; 0.3 or 3 μM), a sarcoplasmic reticulum Ca2+ release inhibitor (ryanodine; 0.3 or 3 μM), a sodium current inhibitor (tetrodotoxin; 1, 3 or 10 μM) and a late sodium current inhibitor (ranolazine; 10 μM). Western blot analysis was used to investigate the protein expression in SANs from normal rabbits and those with HF. Control SANs had a higher beating rate than SANs from rabbits with HF (2.3±0.1 vs. 1.5±0.1 Hz; P<0.001). Similarly, ivabradine (10 μM), KN 93 (3 μM), ranolazine (10 μM) and ryanodine (3 μM) decreased the beating rates of SANs in the control (n=6) and HF (n=6) groups. Ivabradine treatment resulted in a higher incidence of AP block in HF vs. control SANs (66.7 vs. 0%; P<0.05). Tetrodotoxin (1, 3 or 10 μM) decreased the beating rate to a higher extent in SANs from rabbits with HF than in those from control rabbits and induced a higher incidence of AP block (66.7 vs. 0%; P<0.05). Furthermore, SANs from rabbits with HF had higher protein levels of phospholamban (PLB) and lower levels of hyperpolarization activated cyclic nucleotide gated potassium channel 4, ryanodine receptor and phosphorylated PLB than control SANs. In conclusion, HF modulates electropharmacological responses in the SAN by channel regulation, which may result in SAN dysfunction.

Original languageEnglish
Pages (from-to)771-779
Number of pages9
JournalExperimental and Therapeutic Medicine
Volume13
Issue number2
DOIs
Publication statusPublished - Feb 1 2017

Fingerprint

Sinoatrial Node
Heart Failure
ivabradine
Rabbits
Action Potentials
Ryanodine
Tetrodotoxin
Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels
Sodium
Calcium-Calmodulin-Dependent Protein Kinases
Ryanodine Receptor Calcium Release Channel
Potassium Channels
Incidence
Sarcoplasmic Reticulum
Proteins
Western Blotting
Pharmacology

Keywords

  • Heart failure
  • Ivabradine
  • KN-93
  • Ranolazine
  • Ryanodine
  • Tetrodotoxin

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology (miscellaneous)
  • Cancer Research

Cite this

Heart failure modulates electropharmacological characteristics of sinoatrial nodes. / Chang, Shih Lin; Chuang, Hui Lun; Chen, Yao Chang; Kao, Yu Hsun; Lin, Yung Kuo; Yeh, Yung Hsin; Chen, Shih Ann; Chen, Yi Jen.

In: Experimental and Therapeutic Medicine, Vol. 13, No. 2, 01.02.2017, p. 771-779.

Research output: Contribution to journalArticle

Chang, Shih Lin ; Chuang, Hui Lun ; Chen, Yao Chang ; Kao, Yu Hsun ; Lin, Yung Kuo ; Yeh, Yung Hsin ; Chen, Shih Ann ; Chen, Yi Jen. / Heart failure modulates electropharmacological characteristics of sinoatrial nodes. In: Experimental and Therapeutic Medicine. 2017 ; Vol. 13, No. 2. pp. 771-779.
@article{b14bc4c47d9e4340a489fc91557d8077,
title = "Heart failure modulates electropharmacological characteristics of sinoatrial nodes",
abstract = "The impact of heart failure (HF) on sinoatrial node (SAN) channel regulation and electropharmacological responses has remained elusive. The present study aimed to investigate the effects of HF on the electrical activity of SANs with and without pharmacological interventions. Action potentials (APs) were recorded in isolated SANs from normal rabbits (control) and those with HF (rapid ventricular pacing for 4 weeks) prior to and after administration of a funny current blocker (ivabradine; 0.1, 0.3, 3 or 10 μM), a calmodulin kinase II inhibitor (KN 93; 0.3 or 3 μM), a sarcoplasmic reticulum Ca2+ release inhibitor (ryanodine; 0.3 or 3 μM), a sodium current inhibitor (tetrodotoxin; 1, 3 or 10 μM) and a late sodium current inhibitor (ranolazine; 10 μM). Western blot analysis was used to investigate the protein expression in SANs from normal rabbits and those with HF. Control SANs had a higher beating rate than SANs from rabbits with HF (2.3±0.1 vs. 1.5±0.1 Hz; P<0.001). Similarly, ivabradine (10 μM), KN 93 (3 μM), ranolazine (10 μM) and ryanodine (3 μM) decreased the beating rates of SANs in the control (n=6) and HF (n=6) groups. Ivabradine treatment resulted in a higher incidence of AP block in HF vs. control SANs (66.7 vs. 0{\%}; P<0.05). Tetrodotoxin (1, 3 or 10 μM) decreased the beating rate to a higher extent in SANs from rabbits with HF than in those from control rabbits and induced a higher incidence of AP block (66.7 vs. 0{\%}; P<0.05). Furthermore, SANs from rabbits with HF had higher protein levels of phospholamban (PLB) and lower levels of hyperpolarization activated cyclic nucleotide gated potassium channel 4, ryanodine receptor and phosphorylated PLB than control SANs. In conclusion, HF modulates electropharmacological responses in the SAN by channel regulation, which may result in SAN dysfunction.",
keywords = "Heart failure, Ivabradine, KN-93, Ranolazine, Ryanodine, Tetrodotoxin",
author = "Chang, {Shih Lin} and Chuang, {Hui Lun} and Chen, {Yao Chang} and Kao, {Yu Hsun} and Lin, {Yung Kuo} and Yeh, {Yung Hsin} and Chen, {Shih Ann} and Chen, {Yi Jen}",
year = "2017",
month = "2",
day = "1",
doi = "10.3892/etm.2016.4015",
language = "English",
volume = "13",
pages = "771--779",
journal = "Experimental and Therapeutic Medicine",
issn = "1792-0981",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - Heart failure modulates electropharmacological characteristics of sinoatrial nodes

AU - Chang, Shih Lin

AU - Chuang, Hui Lun

AU - Chen, Yao Chang

AU - Kao, Yu Hsun

AU - Lin, Yung Kuo

AU - Yeh, Yung Hsin

AU - Chen, Shih Ann

AU - Chen, Yi Jen

PY - 2017/2/1

Y1 - 2017/2/1

N2 - The impact of heart failure (HF) on sinoatrial node (SAN) channel regulation and electropharmacological responses has remained elusive. The present study aimed to investigate the effects of HF on the electrical activity of SANs with and without pharmacological interventions. Action potentials (APs) were recorded in isolated SANs from normal rabbits (control) and those with HF (rapid ventricular pacing for 4 weeks) prior to and after administration of a funny current blocker (ivabradine; 0.1, 0.3, 3 or 10 μM), a calmodulin kinase II inhibitor (KN 93; 0.3 or 3 μM), a sarcoplasmic reticulum Ca2+ release inhibitor (ryanodine; 0.3 or 3 μM), a sodium current inhibitor (tetrodotoxin; 1, 3 or 10 μM) and a late sodium current inhibitor (ranolazine; 10 μM). Western blot analysis was used to investigate the protein expression in SANs from normal rabbits and those with HF. Control SANs had a higher beating rate than SANs from rabbits with HF (2.3±0.1 vs. 1.5±0.1 Hz; P<0.001). Similarly, ivabradine (10 μM), KN 93 (3 μM), ranolazine (10 μM) and ryanodine (3 μM) decreased the beating rates of SANs in the control (n=6) and HF (n=6) groups. Ivabradine treatment resulted in a higher incidence of AP block in HF vs. control SANs (66.7 vs. 0%; P<0.05). Tetrodotoxin (1, 3 or 10 μM) decreased the beating rate to a higher extent in SANs from rabbits with HF than in those from control rabbits and induced a higher incidence of AP block (66.7 vs. 0%; P<0.05). Furthermore, SANs from rabbits with HF had higher protein levels of phospholamban (PLB) and lower levels of hyperpolarization activated cyclic nucleotide gated potassium channel 4, ryanodine receptor and phosphorylated PLB than control SANs. In conclusion, HF modulates electropharmacological responses in the SAN by channel regulation, which may result in SAN dysfunction.

AB - The impact of heart failure (HF) on sinoatrial node (SAN) channel regulation and electropharmacological responses has remained elusive. The present study aimed to investigate the effects of HF on the electrical activity of SANs with and without pharmacological interventions. Action potentials (APs) were recorded in isolated SANs from normal rabbits (control) and those with HF (rapid ventricular pacing for 4 weeks) prior to and after administration of a funny current blocker (ivabradine; 0.1, 0.3, 3 or 10 μM), a calmodulin kinase II inhibitor (KN 93; 0.3 or 3 μM), a sarcoplasmic reticulum Ca2+ release inhibitor (ryanodine; 0.3 or 3 μM), a sodium current inhibitor (tetrodotoxin; 1, 3 or 10 μM) and a late sodium current inhibitor (ranolazine; 10 μM). Western blot analysis was used to investigate the protein expression in SANs from normal rabbits and those with HF. Control SANs had a higher beating rate than SANs from rabbits with HF (2.3±0.1 vs. 1.5±0.1 Hz; P<0.001). Similarly, ivabradine (10 μM), KN 93 (3 μM), ranolazine (10 μM) and ryanodine (3 μM) decreased the beating rates of SANs in the control (n=6) and HF (n=6) groups. Ivabradine treatment resulted in a higher incidence of AP block in HF vs. control SANs (66.7 vs. 0%; P<0.05). Tetrodotoxin (1, 3 or 10 μM) decreased the beating rate to a higher extent in SANs from rabbits with HF than in those from control rabbits and induced a higher incidence of AP block (66.7 vs. 0%; P<0.05). Furthermore, SANs from rabbits with HF had higher protein levels of phospholamban (PLB) and lower levels of hyperpolarization activated cyclic nucleotide gated potassium channel 4, ryanodine receptor and phosphorylated PLB than control SANs. In conclusion, HF modulates electropharmacological responses in the SAN by channel regulation, which may result in SAN dysfunction.

KW - Heart failure

KW - Ivabradine

KW - KN-93

KW - Ranolazine

KW - Ryanodine

KW - Tetrodotoxin

UR - http://www.scopus.com/inward/record.url?scp=85009348253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009348253&partnerID=8YFLogxK

U2 - 10.3892/etm.2016.4015

DO - 10.3892/etm.2016.4015

M3 - Article

AN - SCOPUS:85009348253

VL - 13

SP - 771

EP - 779

JO - Experimental and Therapeutic Medicine

JF - Experimental and Therapeutic Medicine

SN - 1792-0981

IS - 2

ER -